^99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin : Part III. Clinical trials safety and diagnostic efficacyRAMOS-SUZARTE, M; RODRIGUEZ, N; BORRON, M et al.The Journal of nuclear medicine (1978). 1999, Vol 40, Num 5, pp 768-775, issn 0161-5505Article

^99mTc-labeled murine ior C5 monoclonal Antibody in colorectal carcinoma patients: Pharmacokinetics, biodistribution, absorbed Radiation doses to normal organs and tissues and tumor localizationIZNAGA-ESCOBAR, N; RAMOS-SUZARTE, M; MORALES-MORALES, A et al.Methods and findings in experimental and clinical pharmacology. 2004, Vol 26, Num 9, pp 687-696, issn 0379-0355, 10 p.Article

A phase I study of ^99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptorVALLIS, K. A; REILLY, R. M; CHEN, P et al.Nuclear medicine communications. 2002, Vol 23, Num 12, pp 1155-1164, issn 0143-3636, 10 p.Article

Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin : Part II. Pharmacokinetics and clearancesIZNAGA-ESCOBAR, N; TORRES AROCHA, L. A; MORALES MORALES, A et al.The Journal of nuclear medicine (1978). 1998, Vol 39, Num 11, pp 1918-1927, issn 0161-5505Article